Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Surg Clin North Am. 2024 Oct;104(5):1007-1016. doi: 10.1016/j.suc.2024.05.003. Epub 2024 Jul 20.
Pancreatic adenocarcinoma remains a deadly disease with 5 year overall survival of 10% among all stages. Standard of care for resectable disease remains surgical resection and adjuvant systemic therapy, but paradigms for borderline resectable and unresectable cases remain more nuanced. Radiation has been explored in the neoadjuvant, adjuvant, and definitive settings in a variety of randomized and non-randomized trials with mixed results. There is strong evidence to support the use of neoadjuvant radiation for borderline resectable pancreatic cancer. Utilization of radiation in the adjuvant setting remains unclear while the results of radiation therapy oncology group (RTOG) 0848 are pending.
胰腺腺癌仍然是一种致命疾病，所有阶段的 5 年总生存率为 10%。可切除疾病的标准治疗仍然是手术切除和辅助全身治疗，但边界可切除和不可切除病例的治疗模式仍然更加复杂。在各种随机和非随机试验中，已经在新辅助、辅助和确定性治疗环境中探索了放射治疗，结果喜忧参半。有强有力的证据支持使用新辅助放疗治疗边界可切除的胰腺癌。在辅助治疗环境中使用放疗仍然不清楚，而放射治疗肿瘤学组（RTOG）0848 的结果仍在等待中。
